Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Usability of FYB203 PFS in Retinal Diseases
NCT06708637Phase 4Completed
- Sponsor
- Formycon AG
- Start
- Sep 2024
- Primary completion
- Oct 2024
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 4 trial of baiama in neovascular age-related macular degeneration (NVAMD), macular edema, branch retinal vein occlusion (BRVO), central retinal vein occlusion (CRVO), diabetic macular edema (DME), sponsored by Formycon AG. Started Sep 2024; status: completed.
02
Drugs
baiama
03
Conditions
neovascular age-related macular degeneration (NVAMD)macular edemabranch retinal vein occlusion (BRVO)central retinal vein occlusion (CRVO)diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT06708637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06708637.